Table 2. Treatments and patient outcomes.
| Overall n = 27 | |
|---|---|
| Radiotherapy doses | |
| BED of GTV (Gy), median (range) | 63.65 (48.96–70.20) |
| BED of WBRT (Gy), median (range) | 40.63 (39.00–48.00) |
| Systemic treatment | |
| Chemotherapy | 25 (92.6%) |
| HER2-targeted therapy | 16 (66.7%) |
| VEGFR-2 targeted therapy | 2 (7.4%) |
| Endocrine therapy | 3 (11.1%) |
| TKI treatment for HER2+ (n = 16) | |
| Yes | 14 (87.5%) |
| No | 2 (12.5%) |
| Brain tumor response | |
| Complete response | 4 (14.8%) |
| Partial response | 14 (51.9%) |
| Unevaluated | 9 (33.3%) |
| Neurological side effects | 11 (40.7%) |
| Brain progression | |
| Yes | 19 (70.4%) |
| Unevaluated | 8 (29.6%) |
| Death | |
| Yes | 20 (74.1%) |
| No | 7 (25.9%) |
| Cause of death (n = 20) | |
| Extracranial progression | 15 (75.0%) |
| Intracranial progression | 5 (18.5%) |
Note:
BED, biologically effective dose; GTV, gross tumor volume; HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor; VEGFR-2, vascular endothelial growth factor-2; WBRT, whole brain radiotherapy.